By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Editas Medicine 

300 Third Street, First Floor

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-401-9000 Fax: n/a


SEARCH JOBS

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.

The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.


Key Statistics


Email: dan@purecommunicationsinc.com
Ownership: Private

Web Site: Editas Medicine
Employees: n/a
Symbol: 
 



Industry
Biotechnology

Segment
Genomics
Start Up





Company News
Top 30 Life Science Startups To Watch In The U.S. 10/23/2014 4:27:21 AM
Genome-Editing Company Editas Medicine Brings In Ex-Avila Therapeutics CEO For Top Post 6/24/2014 6:15:51 AM
Editas Medicine Co-Founders Present Novel Methods For Improving Genome Editing Specificity In Two Nature Biotechnology Papers 4/28/2014 8:57:23 AM
Editas Medicine Co-Founder Publishes High-Resolution Structures Of Major Cas9 Enzymes In Science 2/7/2014 8:25:05 AM
Editas Medicine Co-Founder Develops Novel Approach To Increase Specificity Of CRISPR/Cas9 Technology; Findings Published In Nature Biotechnology 1/27/2014 10:04:02 AM
Editas Medicine Co-Founder Develops Novel Approach To Increase Specificity Of CRISPR/Cas9 Technology; Findings Published In Nature Biotechnology 1/27/2014 8:44:04 AM
Three Biotech Startup Creators Throw $43 Million Into Editas Medicine 11/25/2013 8:04:52 AM
//-->